Preventive cardiologist Dr. Himanshu Brahmbhatt and regenerative medicine specialist Dr. Jennifer MacDiarmid have developed an innovative, novel therapy known as EDV. Their breakthrough approach to treating cancer was born through their partnership within the Commonwealth Scientific and Industrial Research Organisation (CSIRO). In clinical trials, this treatment has produced extraordinary outcomes. It saves lives and can cure cancer patients of all stages from multiple kinds of cancer. Unfortunately, despite all the promise and hope behind it, the road for EDV to reach the market has been anything but smooth.
It seems like a long time coming – EDV first started human trials in Melbourne way back in 2009. Today, it is heading toward late-stage trials in Singapore, Australia, and the United States. The U.S. Food and Drug Administration (FDA) has given EDV fast-track status. That major move would accelerate its approval process. Since its launch, over 100 patients have been treated with EDV. Most of these cases have reported favorable results with stable disease or complete response.
A particularly illustrative example is that of Anne Jonas, a patient suffering from end-stage pancreatic cancer. After receiving EDV, she had a miraculous turnaround. She expressed her gratitude for the treatment, stating, “I was tired the next day but I wasn’t feeling sick, I wasn’t nauseous, I wasn’t anything. I’m like, ‘gosh, this is great, I can do this.’”
A third patient, Lois Harris, who fights neuroendocrine cancer, underwent two courses of EDV in Singapore. She reflected on her vision going forward. If I could have an additional 10 or 12 healthy years, that’s a big victory!” she shouted. At my age, I could have gone very quickly into a negative spiral. This gives me the hope of stable disease and lessening symptoms. Harris noted how the treatment has improved her quality of life: “It’s given me a chance to lead a normal life.”
Due to its unusual composition, EDV has a unique institutional foundation. It is in fact an immortal form nano cell that occurs spontaneously from bacteria, one of the smartest immortal cells discovered by science. ICLyte This new treatment acts by starving cancer cells to death while leaving healthy cells unharmed. It spares healthy cells, which makes it a truly groundbreaking new approach in cancer treatment. Dr. Brahmbhatt’s inspiration for developing EDV stemmed from personal loss—his friend succumbed to cancer, igniting his determination to find a cure.
Dr Brahmbhatt and Dr MacDiarmid spent hundreds of nights devising solutions to the problems they encountered at a McDonald’s in Western Sydney. Their commitment and persistence set the stage for this hopeful therapy. All along the way, their progress has faced challenges. Dr. Brahmbhatt acknowledged the challenges faced in getting cancer treatments to market: “It is very difficult to get cancer treatments to market because [cancer is hard to treat].”
Dr. Jim Whittle emphasized the complexity of developing effective cancer therapies due to the diverse nature of cancer itself: “Each cancer behaves differently depending on genetic and environmental factors, and this complexity demands highly specialised clinical trial design and analysis to determine which new treatments are truly an advance on the standard-of-care.” He mentioned how this often cumbersome process can take 10 to 15 years.
Despite these hurdles, Dr. Brahmbhatt remains optimistic about EDV’s potential impact on patients’ lives: “We want to see people go home cancer-free. There is no price that one can put on that.” He expressed concern for those who lose hope in their battle against cancer: “I see those eyes that are losing all hope.”
Despite recent popularity, the future of EDV faces an uncertain path as it continues to avert the rocky waters between medical approval and commercialization. In clinical trials, it has proven to be extremely effective. Like so many great inventions, those innovations disappeared, never getting into the hands of those who need them most. Dr. Brahmbhatt remarked on this reality: “A lot of great inventions vanish before they ever get the chance to help anyone.”
The investment that Dr. Brahmbhatt and Dr. MacDiarmid have made in pursuing this field of cancer treatment is representative of a larger ′cutting-edge′ commitment to discovery science. Dr. Whittle highlighted the importance of continued support for such research: “That is part of what makes it so exciting. Many of tomorrow’s breakthroughs will come from directions we can’t yet anticipate.”
